Allergan Biocell Textured Breast Implant
The Allergan Biocell MDL was centralized in December 2019 to coordinate claims linking the textured surface of certain Allergan breast implants to breast implant-associated anaplastic large cell lymphoma, or BIA-ALCL — a rare form of lymphoma that develops in the scar tissue and fluid surrounding a breast implant, prompting a global recall of the affected products. With 1,370 actions pending, this remains a substantial active docket built on a well-characterized, medically recognized injury mechanism connecting implant surface texture to lymphoma risk.
What drives resolution and duration risk in this docket most directly is the significant heterogeneity within the claims population itself: some claimants have a confirmed BIA-ALCL diagnosis and associated cancer treatment, others have undergone explant surgery as a precautionary measure without a diagnosis, and others are pursuing ongoing-monitoring or increased-risk claims. That range means the docket does not present a single uniform causation or damages question — general causation linking textured implants to elevated BIA-ALCL risk is comparatively well established given the regulatory recall history, but damages and claim strength vary considerably by individual diagnosis and treatment status.
That structure shapes how a comprehensive resolution is likely to be built, if and when one occurs: settlement architecture for a docket like this typically needs tiered compensation categories reflecting diagnosis severity rather than a single flat per-claimant framework, which in turn affects how quickly and predictably the docket can move toward a comprehensive resolution relative to a docket with a more uniform injury profile.
Criterica Intelligence treats claim-population heterogeneity — the range of severity and diagnosis status within a single docket — as a first-order factor in reading resolution-path complexity, distinct from the underlying general-causation question, and surfaces that distinction across every active MDL where it applies, this docket included.
BIA-ALCL is a rare lymphoma that can develop in the tissue and fluid around a textured breast implant; its link to certain Allergan textured implants prompted a global product recall and is the central injury theory behind this MDL.
Claimants range from those with a confirmed cancer diagnosis and treatment history to those who had the implant removed as a precaution or are undergoing ongoing monitoring without a diagnosis, producing a broad severity spectrum within one docket.
It proceeds toward an individual trial, where the well-established general-causation link between textured implants and BIA-ALCL is likely to matter less than the specific diagnosis and damages facts of that claimant's case.
Unlikely — a settlement architecture here would need tiered compensation categories reflecting diagnosis severity, since a confirmed cancer diagnosis and a precautionary explant claim represent very different levels of harm.
Statistics shown reflect historical or illustrative model outputs derived from real case data. They are not predictions or guarantees of any individual outcome. Litigation results depend on facts, jurisdiction, judge, and counsel, and vary case by case. Model accuracy is subject to selection effects and changing legal dynamics.